Nanocarrier systems for delivery of siRNA to ovarian cancer tissues

Bibliography

• Rao DD, Vorhies JS, Senzer N, SiRNA vs.shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61:746-59
   PubMed Web of Science ®Google Scholar
• Numnum TM, Makhija S, Lu B, Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol 2008;108:34-41
   PubMed Web of Science ®Google Scholar
• Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011;6:1130-46
   PubMed Web of Science ®Google Scholar
• Garson K, Shaw TJ, Clark KV, Models of ovarian cancer-Are we there yet? Mol Cell Endocrinol 2005;239:15-26
   PubMed Web of Science ®Google Scholar
• Gorringe KL, Campbella IG. Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 2009;3:157-64
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI Jr, Bast RC, Rethinking ovarian cancer:recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IM. The Origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. Am J Surg Pathol 2010;34:433-43
   PubMed Web of Science ®Google Scholar
• Despierre E, Lambrechts D, Neven P, The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol 2010;117:358-65
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
   PubMed Web of Science ®Google Scholar
• Vanderhyden BC, Dorward AM. Ovarian cancer and the environment: rodent models. In: McQueen CA. editor. Comprehensive Toxicology. Volume 11 2nd edition. Elsevier Ltd; Elsevier: 2010. p. 483-98
   Google Scholar
• Ashworth A, Balkwill F, Bast RC, Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum. Gynecol Oncol 2008;108:652-7
   PubMed Web of Science ®Google Scholar
• Maloney A, Clarke PA, Naaby-Hansen S, Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007;67:3239-53
   PubMed Web of Science ®Google Scholar
• Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control 2011;18:8-15
   PubMedGoogle Scholar
• Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006;32:875-86
   PubMed Web of Science ®Google Scholar
• Disaia PJ, Bloss JD. Treatment of ovarian cancer:new strategies. Gynecol Oncol 2003;90:S24-32
   PubMed Web of Science ®Google Scholar
• Kieback DJ, Hasenburg A, Runnebaum IB, Gene therapy of ovarian cancer-state of the art and future perspectives. In: Altchek A, Deligdisch L, Kase NG, editors. Diagnosis and Management of Ovarian Disorders. 2nd edition. Elsevier Science; USA: 2003. p. 277-304
   Google Scholar
• Sawicki JA, Anderson DG, Langer R. Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy. Adv Exp Med Biol 2008;622:209-19
   PubMed Web of Science ®Google Scholar
• Singh P, Joshi S, Russell P, Purine nucleoside phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer. BMC Cancer 2011;11:368
   PubMedGoogle Scholar
• Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-59
   PubMed Web of Science ®Google Scholar
• Imamura O, Okada H, Takashima Y, SiRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model. Cancer Lett 2008;268:278-85
   PubMed Web of Science ®Google Scholar
• Kenny GD, Kamaly N, Kalber TL, Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release 2011;149:111-16
   PubMed Web of Science ®Google Scholar
• Guo P, Coban O, Snead NM, Engineering RNA for Targeted siRNA delivery and medical application. Adv Drug Deliv Rev 2010;62:650-66
   PubMed Web of Science ®Google Scholar
• Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007;59:164-82
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kanazawa T, Ogaw T, Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing. Int J Pharm 2010;398:219-24
   PubMedGoogle Scholar
• Bhaskar S, Tian F, Stoeger T, Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier:perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010;7:3
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Nanocarriers for drug delivery: needs and requirements. In: Torchilin VP, editor. Nanoparticulates as Drug Carriers. Imperial College Press; World Scientific: 2006. p. 1-6
   Google Scholar
• Cho K, Wang X, Nie S, Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-16
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38
   PubMed Web of Science ®Google Scholar
• David S, Pitard B, Benoit JP, Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res 2010;62:100-14
   PubMed Web of Science ®Google Scholar
• He X, Arslan AD, Pool MD, Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 2011;30:356-65
   Google Scholar
• Liua X, Howard KA, Dong M, The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007;28:1280-8
   PubMed Web of Science ®Google Scholar
• Li S, Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007;123:181-3
   PubMed Web of Science ®Google Scholar
• Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomed Nanotechnol Biol Med 2009;5:8-20
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang L. Tumor-targeted delivery of siRNA by non-viral vector:safe and effective cancer therapy. Expert Opin Drug Deliv 2008;5:1301-11
   PubMed Web of Science ®Google Scholar
• Jain NK, Nahar M. PEGylated nanocarriers for systemic delivery. Methods Mol Biol 2010;624:221-34
   PubMedGoogle Scholar
• Kim PS, Djazayeri S, Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. Gynecol Oncol 2011;120:393-403
   PubMed Web of Science ®Google Scholar
• Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-68
   PubMed Web of Science ®Google Scholar
• Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010;277:4814-27
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148:135-46
   PubMed Web of Science ®Google Scholar
• Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine(Lond) 2010;5:523-8
   PubMed Web of Science ®Google Scholar
• Hong S, Lerouell PR, Majoros IJ. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007;14:107-15
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90-9
   PubMed Web of Science ®Google Scholar
• Martimprey H, Vauthier C, Malvy C, Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm 2009;71:490-504
   PubMed Web of Science ®Google Scholar
• Tarapore P, Shu Y, Guo P, Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and surviving in ovarian cancers. Mol Ther 2011;19:386-94
   PubMed Web of Science ®Google Scholar
• Chen Q, Butler D, Querbes W, Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release 2010;144:227-32
   PubMed Web of Science ®Google Scholar
• Cao A, Briane D, Coudert R. Cationic liposomes as transmembrane carriers of nucleic acids. Adv Planar Lipid Bilayer Liposom 2006;4:136-82
   Google Scholar
• Kim HK, Davaa E, Myung CS, Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm 2010;392:141-7
   PubMed Web of Science ®Google Scholar
• Pozo-Rodriguez A, Delgado D, Angeles Solinis M, Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm 2010;385:157-62
   PubMedGoogle Scholar
• Mevel M, Kamaly N, Carmona S, DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release 2010;143:222-32
   PubMed Web of Science ®Google Scholar
• Xue HY, Wong HL. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011;32:2662-72
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu XL, Li XR. Research progress on siRNA delivery with nonviral carriers. Int J Nanomed 2011;6:1017-25
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiao Y, Wang Y, Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008;60:1650-62
   PubMed Web of Science ®Google Scholar
• Oh JK, Lee DI, Park JM. Biopolymer-based microgels/nanogels for drug delivery applications. Prog Polym Sci 2009;34:1261-82
   Web of Science ®Google Scholar
• Lee DW, Yun K, Ban H, Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release 2009;139:146-52
   PubMed Web of Science ®Google Scholar
• Cohen JL, Schubert S, Wich PR, Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics. Bioconjug Chem 2011;22:1056-65
   PubMed Web of Science ®Google Scholar
• Singh HD, Wang G, Uludag H, Poly-L-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics. Acta Biomater 2010;6:4277-84
   PubMed Web of Science ®Google Scholar
• Eguchi A, Dowdy SF. SiRNA delivery using peptide transduction domains. Trends Pharmacol Sci 2009;30(7):341-5
   PubMed Web of Science ®Google Scholar
• Lochmann D, Jauk E, Zimmer A. Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm 2004;58:237-51
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee JY, Suh JS, The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010;31:1429-43
   PubMed Web of Science ®Google Scholar
• Hobel S, Loos A, Appelhans D, Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): physicochemical and biological properties of DNA and siRNA complexes. J Control Release 2011;149:146-58
   PubMed Web of Science ®Google Scholar
• Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv 2010;7:1209-26
   PubMed Web of Science ®Google Scholar
• Convertine A, Benoit D, Duvall C, Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release 2009;133:221-9
   PubMed Web of Science ®Google Scholar
• Kumar MR, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004;25:1771-7
   PubMed Web of Science ®Google Scholar
• Felber AE, Castagner B, Elsabahy M, SiRNA nanocarriers based on methacrylic acid copolymers. J Control Release 2011;152:159-67
   PubMed Web of Science ®Google Scholar
• Xu ZP, Zeng QH, Lu GQ, Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006;61:1027-40
   Web of Science ®Google Scholar
• Ladewig K, Niebert M, Xu Z, Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Biomaterials 2010;31:1821-9
   PubMed Web of Science ®Google Scholar
• Sun C, Lee J, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008;60:1252-65
   PubMed Web of Science ®Google Scholar
• Figuerola A, Di Corato R, Manna L, From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 2010;62:126-43
   PubMed Web of Science ®Google Scholar
• Li J, Chen Y, Tseng Y, Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010;142:416-21
   PubMed Web of Science ®Google Scholar
• Zhang M, Ishii A, Nishiyama N, PEGylated calcium phosphate nanocomposites as smart environment-sensitive carriers for siRNA delivery. Adv Mater 2009;21:3520-5
   Web of Science ®Google Scholar
• Park K. Systemic siRNA delivery using biocompatible calcium phosphate nanoparticles. J Control Release 2010;142:295
   PubMed Web of Science ®Google Scholar
• Kim D, Kim J, Park M, Modulation of biological processes in the nucleus by delivery of DNA oligonucleotides conjugated with gold nanoparticles. Biomaterials 2011;32:2593-604
   PubMed Web of Science ®Google Scholar
• Duncan B, Kim C, Rotello VM. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release 2010;148:122-7
   PubMed Web of Science ®Google Scholar
• Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 2011;149:65-71
   PubMed Web of Science ®Google Scholar
• Patra CR, Bhattacharya R, Mukhopadhyay D, Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010;62:346-61
   PubMed Web of Science ®Google Scholar
• Ghosh P, Han G, De M, Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008;60:1307-15
   PubMed Web of Science ®Google Scholar
• Tanaka T, Godine B, Bhavane R, In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm 2010;402:190-7
   PubMed Web of Science ®Google Scholar
• Tanaka T, Mangala LS, Vivas-Mejia PE, Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-96
   PubMed Web of Science ®Google Scholar
• Bhattarai SR, Muthuswamy E, Wani A, Enhanced gene and siRNA delivery by polycation-modified mesoporous silica nanoparticles loaded with chloroquine. Pharm Res 2010;27:2556-68
   PubMed Web of Science ®Google Scholar
• Cheung W, Pontoriero F, Taratula O, DNA and carbon nanotubes as medicine. Adv Drug Deliv Rev 2010;62:633-49
   PubMed Web of Science ®Google Scholar
• Hossain S, Stanislaus A, Chua MJ, Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release 2010;147:101-8
   PubMed Web of Science ®Google Scholar
• Jayakumar R, Chennazhi KP, Muzzarelli RAA, Chitosan conjugated DNA nanoparticles in gene therapy. Carbohydr Polym 2010;79:1-8
   Web of Science ®Google Scholar
• Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm 2010;399:1-11
   PubMed Web of Science ®Google Scholar
• Lai W, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release 2009;134:158-68
   PubMed Web of Science ®Google Scholar
• Kim T, Jiang H, Jere D, Chemical modification of chitosan as a gene carrier in vitro and in vivo. Prog Polym Sci 2007;32:726-53
   Web of Science ®Google Scholar
• Noh SM, Park MO, Shim G, Pegylated poly-L-arginine derivatives of chitosan for effective delivery of siRNA. J Control Release 2010;145:159-64
   PubMed Web of Science ®Google Scholar
• Nafee N, Taetz S, Schneider M, Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomed Nanotechnol Biol Med 2007;3:173-83
   PubMed Web of Science ®Google Scholar
• Tahara K, Sakai T, Yamamoto H, Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 2008;354:210-16
   PubMed Web of Science ®Google Scholar
• Tan ML, Choong P, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009;61:3-12
   PubMed Web of Science ®Google Scholar
• Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 2009;71:257-63
   PubMed Web of Science ®Google Scholar
• Duceppe N, Tabrizian M. Factors influencing the transfection efficiency of ultra low molecular weight chitosan/hyaluronic acid nanoparticles. Biomaterials 2009;30:2625-31
   PubMed Web of Science ®Google Scholar
• Gazori T, Haririan I, Fouladde S, Inhibition of EGFR expression with chitosan/alginate nanoparticles encapsulating antisense oligonucleotides in T47D cell line using RT-PCR and immunocytochemistry. Carbohydr Polym 2010;80:1042-7
   Web of Science ®Google Scholar
• Urban-Klein B, Werth S, Abuharbeid S, RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12:461-6
   PubMed Web of Science ®Google Scholar
• Sudimack BAJ, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-62
   PubMed Web of Science ®Google Scholar
• Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001;6:44-51
   PubMed Web of Science ®Google Scholar
• Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev 2006;58:487-99
   PubMed Web of Science ®Google Scholar
• Cun D, Jensen DK, Maltesen MJ, High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur J Pharm Biopharm 2011;77:26-35
   PubMed Web of Science ®Google Scholar
• Cun D, Foged C, Yang M, Preparation and characterization of poly(dl-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm 2010;390:70-5
   PubMed Web of Science ®Google Scholar
• Young S, Wong M, Tabata Y, Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 2005;109:256-74
   PubMed Web of Science ®Google Scholar
• Zillies J, Coester C. Evaluating gelatine based nanoparticles as a carrier system for double stranded oligonucleotides. J Pharm Pharm Sci 2005;7:17-21
   PubMedGoogle Scholar
• Kushibiki T, Nagata-Nakajima N, Sugai M, Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-h type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds. J Control Release 2006;110:610-17
   PubMed Web of Science ®Google Scholar
• Ofokansi K, Winter G, Fricker G, Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharm Biopharm 2010;76:1-9
   PubMed Web of Science ®Google Scholar
• Zeineldin R, Muller CY, Stack MS, Targeting the EGF receptor for ovarian cancer therapy. J Oncol 2010;2010:1-11
   Google Scholar
• Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010;146:264-75
   PubMed Web of Science ®Google Scholar
• Krieger ML, Eckstein N, Schneider V, Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 2010;389:10-17
   PubMed Web of Science ®Google Scholar
• Han HD, Mangala LS, Lee JW, Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22
   PubMed Web of Science ®Google Scholar
• Dickerson EB, Blackburn WH, Smith MH, Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 2010;10:1-11
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong JH, Lee SH, LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem 2008;19:2156-62
   PubMed Web of Science ®Google Scholar
• Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Nanotechnology and aptamers:applications in drug delivery. Trends Biotechnol 2008;26:442-9
   PubMed Web of Science ®Google Scholar
• Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002;277:46974-9
   PubMed Web of Science ®Google Scholar
• Scarberry KE, Dickerson EB, McDonald JF, Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc 2008;130:10258-62
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zong Z, Xu H. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol 2010;116:563-71
   PubMed Web of Science ®Google Scholar
• Merritt WM, Lin YG, Spannuth WA, Effect of interleukin-8 gene silencing with liposome encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100:359-72
   PubMed Web of Science ®Google Scholar
• Landen Jr CN, Chavez-Reyes A, Bucana C, Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-08
   PubMed Web of Science ®Google Scholar
• Landen CN, Merritt WM, Mangala LS, Intraperitoneal Delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006;5:1708-13
   PubMed Web of Science ®Google Scholar
• Mangala LS, Han HD, Berestein G, Liposomal siRNA for Ovarian Cancer. Therapeutic Applications of RNAi: Methods and Protocols. Volume 555 Humana Press, a part of Springer Science Business Media, LLC; New York: 2009. p. 29-42
   Google Scholar
• Halder J, Kamat AA, Landen CN Jr, Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24
   PubMed Web of Science ®Google Scholar
• Rose SL, Kunnimalaiyaan M, Drenzek J, Notch 1 signaling is active in ovarian cancer. Gynecol Oncol 2010;117:130-3
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Xinga D, Ren Y, Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci 2011;108:745-50
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Mangala LS, Stone RL, Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 2010;9:2377-88
   PubMed Web of Science ®Google Scholar
• Landen CN Jr, Goodman B, Katre AA, Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010;9:3186-99
   PubMedGoogle Scholar
• Feo AD, Huang F, Sangodkar J, KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer. Model Cancer Res 2009;69:4733-41
   PubMed Web of Science ®Google Scholar
• Ye S, Hao X, Zhou T, Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer 2010;10:611-22
   PubMedGoogle Scholar
• Han HD, Mangala LS, Lee JW, Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22
   PubMed Web of Science ®Google Scholar
• Sood AK, Mangala LS, Han H, In vivo angiogenic gene silencing using chitosan nanoparticles in ovarian carcinoma. Gynecol Oncol 2009;112:S2-S185
   PubMedGoogle Scholar
• Kim SW, Kim NY, Choi YB, RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release 2010;143:335-43
   PubMed Web of Science ®Google Scholar
• Patil ML, Zhang M, Minko T. Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano 2011;5:1877-87
   PubMed Web of Science ®Google Scholar
• Blackburn WH, Dickerson EB, Smith MH, Peptide functionalized nanogels for targeted siRNA delivery. Bioconjug Chem 2009;20:960-8
   PubMed Web of Science ®Google Scholar
• Chen AM, Zhang M, Wei D, Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy inmultidrug-resistant cancer cells. Small 2009;5:2673-7
   PubMed Web of Science ®Google Scholar